

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

ATTORNEY'S DKT No.  
001560-376APPLICATION NO.  
09/424,059APPLICANT  
Yoichi NUNOKAWA et alFILING DATE  
November 18, 1999GROUP  
1624**RECEIVED**

OCT 15 2002

OCT 16 2002

**U.S. PATENT DOCUMENTS**

TECH CENTER 1600/290L

Examiner Initials	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication (MM-DD-YYYY)
	Number	Kind Code (if known)		

**FOREIGN PATENT DOCUMENTS**

Examiner Initials	Foreign Patent Document		Country	Date of Publication (MM-DD-YYYY)	Translation	
	Number	Kind Code (if known)			Yes	No
TNT	62-286949		JP	12-12-1987	Abstract Only	

**NON-PATENT LITERATURE DOCUMENTS**

Examiner Initials	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
TNT	✓ Salvador Moncada, M.D., et al, "The L-Arginine-Nitric Oxide Pathway," The New England Journal of Medicine, Vol. 329, No. 27, pp. 2002-2012, 1993.
	✓ Ulrich Forstermann et al, "Properties, Cellular Distribution and Expressional Control," Biochemical Pharmacology, Vol. 50, No. 9, pp. 1321-1332, 1995.
	✓ V. Cattell et al, "Inducible Nitric Oxide Synthase in Inflammation," Histochemical Journal, Vol. 27, pp. 777-784, 1995.
	✓ Andreas K. Nussler et al, "Inflammation, Immunoregulation, and Inducible Nitric Oxide Synthase," Journal of Leukocyte Biology, Vol. 54, pp. 171-178, 1993.
	✓ S. Moncada et al, "Molecular Mechanisms and Therapeutic Strategies Related to Nitric Oxide," The FASEB Journal, Vol. 9, pp. 1319-1330, 1995.
	✓ Xiao-qing Wei et al, "Altered Immune Responses in Mice Lacking Inducible Nitric Oxide Synthase," Nature, Vol. 375, pp. 408-411, 1995.
	✓ Jill E. Ogden et al, "Inhibition of Nitric Oxide Synthase - Potential for a Novel Class of Therapeutic Agent," Tibtech, Vol. 13, pp. 70-78, 1995.
	✓ R. Davis Manning, Jr. et al, "Cardiovascular Responses to Long-Term Blockade of Nitric Oxide Synthesis," Hypertension, Vol. 22, No. 1, pp. 40-48, 1993.
	✓ Garry J. Southan et al, "Selective Pharmacological Inhibition of Distinct Nitric Oxide Synthase Isoforms," Biochemical Pharmacology, Vol. 51, pp. 383-394, 1996.
	✓ Pierre Vassalli et al, "The Pathophysiology of Tumor Necrosis Factors," Annu. Rev. Immunol., Vol. 10, pp. 411-452, 1992.
	✓ Yasutoshi Muto et al, "Enhanced Tumour Necrosis Factor and Interleukin-1 in Fulminant Hepatic Failure," The Lancet, pp. 72-74, 1998.
	✓ Mohammad K. Sharief, M.B. et al, "Association Between Tumor Necrosis Factor- $\alpha$ and Disease Progression in Patients with Multiple Sclerosis," Vol. 325, No. 7, pp. 467-472, 1991.
	✓ Ciro Tetta et al, "Tumour Necrosis Factor in Serum and Synovial Fluid of Patients with Active and Severe Rheumatoid Arthritis," Annals of the Rheumatic Diseases, Vol. 49, pp. 665-667, 1990.
	✓ G. Venn et al, "Elevated Synovial Fluid Levels of Interleukin-6 and Tumor Necrosis Factor Associated with Early Experimental Canine Osteoarthritis," Arthritis and Rheumatism, Vol. 36, No. 6, pp. 819-826, 1993.
TNT	✓ Michael J. Elliott et al, "Repeated Therapy with Monoclonal Antibody to Tumour Necrosis Factor $\alpha$ (cA2) in patients with Rheumatoid Arthritis," The Lancet, Vol. 344, pp. 1125-1127, 1994.


EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Substitute for form 1449A/PTO

ATTORNEY's DKT No.  
001560-376APPLICATION No.  
09/424,059INFORMATION DISCLOSURE  
STATEMENT BY APPLICANTAPPLICANT  
Yoichi NUNOKAWA et alFILING DATE  
November 18, 1999GROUP  
1624

OCT 16 2002

TECH CENTER 1600/2



<input checked="" type="checkbox"/> Michael J. Elliott et al, "Randomised Double-Blind Comparison of Chimeric Monoclonal Antibody to Tumour Necrosis Factor $\alpha$ (cA2) Versus Placebo in Rheumatoid Arthritis," <i>The Lancet</i> , Vol. 344, pp. 1105-1110, 1994.
<input checked="" type="checkbox"/> E. C. C. Rankin et al, "The Therapeutic Effects of an Engineered Human Anti-Tumour Necrosis Factor Alpha Antibody (CDP571) in Rheumatoid Arthritis," <i>British Journal of Rheumatology</i> , Vol. 34, pp. 334-342, 1995.
<input checked="" type="checkbox"/> Jean-Louis Vincent, M.D. et al, "Administration of Anti-TNF Antibody Improves Left Ventricular Function in Septic Shock Patients," <i>Chest</i> , Vol. 101, No. 3, pp. 810-815, 1992.
<input checked="" type="checkbox"/> L.B. Hinshaw et al, "Survival of Primates in LD <sub>100</sub> Septic Shock Following Therapy with Antibody to Tumor Necrosis Factor (TNF $\alpha$ )," <i>Circulatory Shock</i> , Vol. 30, pp. 279-292, 1990.
<input checked="" type="checkbox"/> J. Nyman et al, "Amelioration of Collagen II-Induced Arthritis in Rats by the Type IV Phosphodiesterase Inhibitor Rolipram," <i>Clin. Exp. Immunol.</i> Vol. 108, pp. 415-419, 1997.
<input checked="" type="checkbox"/> Timothy S. Blackwell et al, "The Role of Nuclear Factor- $\kappa$ B in Cytokine Gene Regulation," <i>Am. J. Respir. Cell Mol. Biol.</i> , Vol. 17, pp. 3-9, 1997.
<input checked="" type="checkbox"/> C. Victor Jongeneel, "Regulation of the TNF $\alpha$ Gene," <i>Bacterial Endotoxins: Basic Science to Anti-Sepsis Strategies</i> , pp. 367-381, 1994.
<input checked="" type="checkbox"/> Qiao-wen Xie et al, "Role of Transcription Factor NF- $\kappa$ B/Rel in Induction of Nitric Oxide Synthase," <i>The Journal of Biological Chemistry</i> , Vol. 269, No. 7, pp. 4705-4708, 1994.
<input checked="" type="checkbox"/> Yoichi Nunokawa et al, "Human Inducible Nitric Oxide Synthase Gene is Transcriptionally Regulated by Nuclear Factor- $\kappa$ B Dependent Mechanism," <i>Biochemical and Biophysical Research Communications</i> , Vol. 223, pp. 347-352, 1996.
<input checked="" type="checkbox"/> Tucker Collins et al, "Transcriptional Regulation of Endothelial Cell Adhesion Molecules: NF- $\kappa$ B and Cytokine-Inducible Enhancers," <i>The FASEB Journal</i> , Vol. 9, pp. 899-909, 1995.
<input checked="" type="checkbox"/> Patrick A. Baeuerle et al, "NF- $\kappa$ B as a Frequent Target for Immunosuppressive and Anti-Inflammatory Molecules," <i>Advances in Immunology</i> , Vol. 65, pp. 111-137, 1997.
<input checked="" type="checkbox"/> Bruce J. Dezube et al, "Cytokine Dysregulation in AIDS: In Vivo Overexpression of mRNA of Tumor Necrosis Factor- $\alpha$ and Its Correlation with That of the Inflammatory Cytokine GRO," <i>Journal of Acquired Immune Deficiency Syndromes</i> , Vol. 5, pp. 1099-1104, 1992.
<input checked="" type="checkbox"/> Gary Nabel et al, "An Inducible Transcription Factor Activates Expression of Human Immunodeficiency Virus in T Cells," <i>Nature</i> , Vol. 326, pp. 711-713, 1987.
<input checked="" type="checkbox"/> Faterneh Fazely et al, "Pentoifylline (Trental) Decreases the Replication of the Human Immunodeficiency Virus Type 1 in Human Peripheral Blood Mononuclear Cells and in Cultured T Cells," <i>Blood</i> , Vol. 77, No. 8, pp. 1653-1656, 1991.
<input checked="" type="checkbox"/> Eduardo Munoz et al, "Activation of NF- $\kappa$ B by the Tax Protein of HTLV-1," <i>Immunobiol.</i> Vol. 193, pp. 128-136, 1995.
<input checked="" type="checkbox"/> Nathalie Auphan et al, "Immunosuppression by Glucocorticoids: Inhibition of NF- $\kappa$ B Activity Through Induction of I $\kappa$ B Synthesis," <i>Science</i> , Vol. 270, pp. 286-290, 1995.
<input checked="" type="checkbox"/> Rodney E. Shackelford et al, "Aspirin Inhibits Tumor Necrosis Factor- $\alpha$ Gene Expression in Murine Tissue Macrophages," <i>Molecular Pharmacology</i> , Vol. 52, pp. 421-429, 1997.
<input checked="" type="checkbox"/> Vira Bitko et al, "Transcriptional Induction of Multiple Cytokines by Human Respiratory Syncytial Virus Requires Activation of NF- $\kappa$ B and is Inhibited by Sodium Salicylate and Aspirin," <i>Virology</i> , Vol. 232, pp. 369-378, 1997.
<input checked="" type="checkbox"/> Kenji Suzuki et al, "2-Arylmethyl-1,4-benzoquinones. I. Novel Inhibitors of Platelet Aggregation: Synthesis and Pharmacological Evaluation," <i>Chem. Pharm. Bull.</i> Vol. 44, No. 1, pp. 139-144, 1996.
<input checked="" type="checkbox"/> Mario C. Filion et al, "Anti-Inflammatory Activity of Cationic Lipids," <i>British Journal of Pharmacology</i> , Vol. 122, pp. 551-557, 1997.
<input checked="" type="checkbox"/> Peter W. Tsao et al, "The Effect of Dexamethasone on the Expression of Activated NF- $\kappa$ B in Adjuvant Arthritis," <i>Clinical Immunology and Immunopathology</i> , Vol. 83, No. 2, pp. 173-178, 1997.
<input checked="" type="checkbox"/> Salvatore Cuzzocrea et al, "Antiinflammatory Effects of Mercaptoethylguanidine, A Combined Inhibitor of Nitric Oxide Synthase and Peroxynitrite Scavenger, in Carrageenan-Induced Models of Inflammation," <i>Free Radical Biology &amp; Medicine</i> , Vol. 24, No. 3, pp. 450-459, 1998.
<input checked="" type="checkbox"/> Yoshiki Sawa et al, "A Novel Strategy for Myocardial Protection Using In Vivo Transfection of c <sup>is</sup> Element 'Decoy' Against NfkB Binding Site," <i>Circulation</i> , Vol. 96, No. 9, pp. II-280-II-285, 1997.
<input checked="" type="checkbox"/> Toshihiro Nakajima et al, "ES510 Antagonizes Thrombin Receptor Signals by Inhibiting NF- $\kappa$ B Activation," <i>Biochemical and Biophysical Research Communications</i> , Vol. 203, No. 2, pp. 1181-1187, 1994.

Examiner  
SignatureDate  
Considered

12/12/02

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.